Supermarket shelves are full of largely unregulated probiotics that aim to keep gut bacteria in balance. With its new drug Vowst, Seres has created something different: the first oral prescription treatment for the microbiome. Approved by the FDA in April, Vowst is a capsule full of carefully selected bacterial spores that together can suppress growth of C. difficile, which can cause life-threatening infections, and are a common complication in hospitals. In studies, Vowst was 88% effective in preventing repeat infections after two months. “This is a game changer for this patient population,” says Eric Shaff, president and CEO of Seres. It will be available starting in June.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
- Cybersecurity Experts Are Sounding the Alarm on DOGE
- Meet the 2025 Women of the Year
- The Harsh Truth About Disability Inclusion
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- How to Get Better at Doing Things Alone
- Michelle Zauner Stares Down the Darkness
